Jaguar Health Inc (NASDAQ:JAGX)
The stock rose 18.74% to $0.49, thus pushing Jaguar’s market cap up to more than $32.7 million. The gains put Jaguar’s stock gains so far this year at 28.4%. Over the last 12 months, Jaguar shares have dipped to a low of $0.34 and peaked at a high of $1.53.
Jaguar Health Inc (NASDAQ:JAGX) is a pharmaceuticals company focused on the developing and commercializing of innovative gastrointestinal treatments for human and veterinary use.
Regaining rights to Mytesi
On September 25, Jaguar Health Inc (NASDAQ:JAGX) announced that its 100% owned subsidiary Napo Pharmaceuticals has retaken certain rights to crofelemer, the active ingredient in Mytesi, from Glenmark Pharmaceuticals. In a 2005 agreement, Jaguar licensed certain rights tied to development and commercialization of crofelemer to Glenmark, which is based in India. Some of those rights have been returned to Jaguar, bolstering its control of Mytesi – a relief of diarrhea in HIV patients.
The amended agreement with Glenmark returns to Jaguar Health Inc (NASDAQ:JAGX) commercial rights to crofelemer in 141 countries, including India. Glenmark is Napo’s primary manufacturer of crofelemer. Under the 2015 agreement, Glenmark retained development and commercialization rights to crofelemer in India and 140 other countries in the emerging world. The commercial rights to crofelemer in India and those other 140 countries are returning to Jaguar.
Global control of Mytesi
Retaking the rights from Glenmark now gives Jaguar Health Inc (NASDAQ:JAGX) commercial control of Mytesi for all indications globally.
Jaguar Health Inc (NASDAQ:JAGX)’s Mytesi is approved in the U.S. for relief of noninfectious diarrhea in adults with HIV who are on antiretroviral therapy. Jaguar, alongside its Napo subsidiary, is working to expand the treatment label of Mytesi so that it can squeeze even more revenue from the product. For example, Jaguar is pursuing approval of Mytesi for treatment of chemotherapy-induced diarrhea (CID).
In addition to CID, Jaguar Health Inc (NASDAQ:JAGX) is also working to have Mytesi cleared for use in infants and children with short bowel syndrome (SBS). The company is also developing Mytesi for treatment of a wide range of other indications – all of which it now has global commercial control following the retaking of crofelemer rights from Glenmark.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.